Biocon buys Viatris biosimilars unit for $3.34 bln; Infosys launches 'Metaverse

Biocon Biologics has struck a $3.335 billion cash-and-stock deal with US pharmaceuticals company Viatris to acquire its global biosimilars business including rights in the partnered in-licensed portfo

Feb 28, 2022, 12:05 IST
New

Forbes India Podcasts

From the Bookshelves

Forbes India Tech conversations

Money Talks

One thing today in Tech